Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)

被引：27

作者：

Christian, Meier ^{[1
,2
]}

Brigitte, Uebelhart ^{[3
,4
]}

Berengere, Aubry-Rozier ^{[5
]}

Martin, Birkhauser ^{[6
]}

Heike, Bischoff-Ferrari A. ^{[7
,8
]}

Diana, Frey ^{[9
]}

Reto, Kressig W. ^{[10
]}

Olivier, Lamy ^{[5
]}

Kurt, Lippuner ^{[11
,12
]}

Petra, Stute ^{[13
]}

Norbert, Suhm ^{[14
]}

Serge, Ferrari ^{[3
,4
]}

机构：

[1] Univ Hosp, Div Endocrinol Diabetol & Metab, Basel, Switzerland

[2] Univ Basel, Basel, Switzerland

[3] Univ Hosp, Serv Bone Dis, Geneva, Switzerland

[4] Fac Med Geneva, Geneva, Switzerland

[5] Lausanne Univ Hosp, Ctr Bone Dis, Lausanne, Switzerland

[6] Univ Bern, Gynaecol Endocrinol & Reprod Med, Basel, Switzerland

[7] Univ Zurich, Dept Geriatr & Aging Res, Zurich, Switzerland

[8] Univ Hosp Zurich, Zurich, Switzerland

[9] Univ Hosp Zurich, Div Rheumatol, Zurich, Switzerland

[10] Univ Basel, Basel Mobil Ctr, Univ Ctr Med Aging, Basel, Switzerland

[11] Univ Hosp, Dept Osteoporosis, Bern, Switzerland

[12] Univ Bern, Bern, Switzerland

[13] Womens Univ Hosp, Div Gynaecol Endocrinol & Reprod Med, Bern, Switzerland

[14] Univ Hosp Basel, Geriatr Fracture Ctr, Dept Orthopaed & Traumatol, Basel, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2017年 / 147卷

关键词：

osteoporosis; fractures; treatment; bisphosphonates; denosumab; MENOPAUSAL HORMONE-THERAPY; POSTMENOPAUSAL OSTEOPOROSIS; ZOLEDRONIC ACID; BONE-DENSITY; FRACTURES; WOMEN; TERIPARATIDE; DENOSUMAB; EXTENSION; HEALTH;

D O I：

10.4414/smw.2017.14484

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation. Based on the available evidence, this position statement will focus on the long-term management of osteoporosis therapy, formulating decision criteria for clinical practice.

引用

页数：6

共 39 条

[1] Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].